PBYI vs. GALT, IVA, CAPR, VERU, OGI, ATOS, OMER, ZVRA, TRVI, and CDT
Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Galectin Therapeutics (GALT), Inventiva (IVA), Capricor Therapeutics (CAPR), Veru (VERU), Organigram (OGI), Atossa Therapeutics (ATOS), Omeros (OMER), Zevra Therapeutics (ZVRA), Trevi Therapeutics (TRVI), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical preparations" industry.
Galectin Therapeutics (NASDAQ:GALT) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.
Galectin Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 294.27%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 80.41%. Given Puma Biotechnology's higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Puma Biotechnology.
11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 52.7% of Galectin Therapeutics shares are held by insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Galectin Therapeutics had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 6 mentions for Galectin Therapeutics and 5 mentions for Puma Biotechnology. Galectin Therapeutics' average media sentiment score of 0.80 beat Puma Biotechnology's score of 0.57 indicating that Puma Biotechnology is being referred to more favorably in the news media.
Galectin Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
Puma Biotechnology has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Puma Biotechnology received 192 more outperform votes than Galectin Therapeutics when rated by MarketBeat users. Likewise, 66.54% of users gave Puma Biotechnology an outperform vote while only 60.00% of users gave Galectin Therapeutics an outperform vote.
Puma Biotechnology has a net margin of 6.79% compared to Puma Biotechnology's net margin of 0.00%. Galectin Therapeutics' return on equity of 35.49% beat Puma Biotechnology's return on equity.
Summary
Puma Biotechnology beats Galectin Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Puma Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Puma Biotechnology Competitors List
Related Companies and Tools
